RXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 Guidance
Rhea-AI Summary
RxSight (NASDAQ: RXST) reported 2025 results: full-year revenue of $134.5 million (down 4%), gross profit of $103.0 million (76.6% margin), and a net loss of $38.9 million (‑$0.95 per share).
LAL unit sales rose 12% to 109,615 units; LDD system sales fell 48% with 163 units. Cash and short-term investments totaled $228.1 million. 2026 guidance: revenue $120.0–$135.0 million, gross margin 70%–72%, operating expenses $150.0–$160.0 million.
Positive
- LAL unit sales +12% to 109,615 units in 2025
- Gross profit of $103.0M, gross margin improved to 76.6%
- Cash, cash equivalents and short-term investments of $228.1M
Negative
- Full-year revenue declined 4% to $134.5M
- LDD system sales down 48% (163 units) in 2025
- Net loss widened to $38.9M (‑$0.95 per share) in 2025
Market Reaction – RXST
Following this news, RXST has declined 14.64%, reflecting a significant negative market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $7.52. This price movement has removed approximately $53M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
RXST gained 1.02% ahead of earnings while peers were mixed: DCTH +1.84%, BFLY +1.37%, SENS +1.93% in momentum scanners, but CBLL and NPCE were slightly negative. With only one peer in momentum and no same-direction cluster, action appeared company-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings date notice | Neutral | -2.2% | Announcement of scheduled Q4 and full-year 2025 earnings call and webcast. |
| Jan 02 | Conference presentation | Neutral | +0.8% | J.P. Morgan Healthcare Conference presentation with webcast access details. |
| Dec 22 | CFO transition | Neutral | +1.7% | Planned CFO transition with consulting role and highlighted operating progress. |
| Nov 20 | Conference appearance | Neutral | -5.8% | Piper Sandler conference presentation announcement with webcast information. |
| Nov 05 | Q3 2025 earnings | Negative | -7.3% | Q3 2025 revenue decline, lower LDD sales, higher gross margin, and narrowed guidance. |
Recent news has sometimes triggered notable downside on financial updates, as seen with the -7.33% reaction to Q3 2025 results and -5.79% after a conference presentation.
Over the past several months, RxSight announcements have centered on conferences, leadership changes, and financial updates. The Q3 2025 earnings release highlighted revenue decline and wider losses, with the stock falling 7.33%. A Piper Sandler conference appearance coincided with a 5.79% drop, while a CFO transition announcement saw a modest 1.66% gain. The latest article delivers full-year 2025 results, details LAL and LDD unit trends, and introduces 2026 revenue and expense guidance, extending the narrative of growing lens adoption alongside pressured system sales and ongoing losses.
Market Pulse Summary
The stock is dropping -14.6% following this news. A negative reaction despite growing lens volume and higher gross margins would fit prior patterns where financial updates coincided with notable pullbacks, such as the -7.33% move after Q3 2025 results. Investors may focus on declining LDD revenue, reduced 2026 revenue expectations, and widening net losses. The stock’s position well below its 52-week high could amplify sensitivity to concerns about growth quality and the pace toward profitability.
Key Terms
adjusted net loss financial
stock-based compensation financial
AI-generated analysis. Not financial advice.
ALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025.
Strategic Highlights and Recent Developments
- 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased
12% to 109,615 - Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practice
- Light Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growth
- RxSight’s FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from contemporary toric IOLs, were accepted for publication in the Journal of Cataract & Refractive Surgery
- Regulatory approval received in Australia, expanding the company’s addressable international opportunity
“Based on our fourth quarter results, we believe that the commercial initiatives implemented in the second half of 2025 are showing early signs of progress,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “While there is still more work ahead, full year LAL growth reflected strong adoption as physicians and patients recognize the value of the company’s differentiated therapy. Our team remains committed to driving the disciplined execution that supports doctors as they deliver the benefits of high-quality customized vision to their patients.”
Fiscal Year 2025 Financial Results
Full-year 2025 global sales of
2025 gross profit was
Operating expenses for 2025 were
In 2025, net loss was
As of December 31, 2025, cash, cash equivalents and short-term investments totaled
Fourth Quarter Financial Results
In the fourth quarter of 2025, total revenue was
Fourth quarter gross profit was
Total operating expenses were
In the fourth quarter of 2025, the company reported a net loss of
Unit Sales Summary
| Product | 2025 Units Sold | YoY Change vs. 2024 | Q4 2025 Units Sold | YoY Change vs. Q4 2024 | QoQ Change vs. Q3 2025 |
| Light Adjustable Lenses | 109,615 | + | 28,611 | ( | + |
| Light Delivery Devices | 163 | ( | 25 | ( |
2026 Guidance
The company provided its full year 2026 financial guidance as follows:
- Revenue of
$120.0 t o$135.0 million , reflecting lower year-over-year LDD placements; - Gross margin of
70% to72% , driven by higher per-unit manufacturing costs associated with lower LDD production volumes; - Operating expenses of
$150.0 million to$160.0 million ; and - Non-cash stock-based compensation expense of
$30.0 million to$32.0 million .
Conference Call
On Wednesday, February 25, 2026, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its fourth quarter and full year 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: statements regarding the company’s expectations that commercial initiatives implemented in the second half of 2025 are showing early signs of progress; statements relating to 2025 LAL growth and adoption trends in the United States; and statements concerning the company’s commitment to disciplined execution in support of physicians delivering customized vision solutions to their patients. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part I, Item 1A (Risk Factors) in the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
| RxSight, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) (In thousands, except share and per share amounts) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Sales | $ | 32,607 | $ | 40,214 | $ | 134,479 | $ | 139,927 | |||||||
| Cost of sales | 7,344 | 11,426 | 31,470 | 40,984 | |||||||||||
| Gross profit | 25,263 | 28,788 | 103,009 | 98,943 | |||||||||||
| Operating expenses: | |||||||||||||||
| Selling, general and administrative | 27,694 | 28,209 | 112,651 | 101,434 | |||||||||||
| Research and development | 8,905 | 9,208 | 38,549 | 34,367 | |||||||||||
| Total operating expenses | 36,599 | 37,417 | 151,200 | 135,801 | |||||||||||
| Loss from operations | (11,336 | ) | (8,629 | ) | (48,191 | ) | (36,858 | ) | |||||||
| Other income (expense), net: | |||||||||||||||
| Interest expense | (4 | ) | (5 | ) | (19 | ) | (21 | ) | |||||||
| Interest and other income | 2,195 | 2,708 | 9,332 | 9,474 | |||||||||||
| Loss before income taxes | (9,145 | ) | (5,926 | ) | (38,878 | ) | (27,405 | ) | |||||||
| Income tax expense | 6 | 12 | 66 | 50 | |||||||||||
| Net loss | $ | (9,150 | ) | $ | (5,938 | ) | $ | (38,944 | ) | $ | (27,455 | ) | |||
| Other comprehensive (loss) income | |||||||||||||||
| Unrealized (loss) gain on short-term investments | (13 | ) | (344 | ) | (136 | ) | 180 | ||||||||
| Foreign currency translation gain (loss) | 5 | (12 | ) | 23 | (9 | ) | |||||||||
| Total other comprehensive (loss) income | (8 | ) | (356 | ) | (113 | ) | 171 | ||||||||
| Comprehensive loss | $ | (9,159 | ) | $ | (6,294 | ) | $ | (39,057 | ) | $ | (27,284 | ) | |||
| Net loss per share: | |||||||||||||||
| Basic and diluted | $ | (0.22 | ) | $ | (0.15 | ) | $ | (0.95 | ) | $ | (0.71 | ) | |||
| Weighted-average shares used in computing net loss per share: | |||||||||||||||
| Attributable to common stock, basic and diluted | 41,175,725 | 40,356,756 | 40,850,739 | 38,867,726 | |||||||||||
| RxSight, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share amounts) | |||||||
| December 31, | December 31, | ||||||
| 2025 | 2024 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 19,949 | $ | 16,706 | |||
| Short-term investments | 208,179 | 220,517 | |||||
| Accounts receivable | 23,383 | 30,050 | |||||
| Inventories, net | 31,559 | 22,009 | |||||
| Prepaid and other current assets | 4,389 | 4,541 | |||||
| Total current assets | 287,459 | 293,823 | |||||
| Property and equipment, net | 13,056 | 12,413 | |||||
| Operating leases right-of-use assets | 9,959 | 11,217 | |||||
| Restricted cash | 750 | 750 | |||||
| Other assets | 590 | 360 | |||||
| Total assets | $ | 311,814 | $ | 318,563 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 5,296 | $ | 4,544 | |||
| Accrued expenses and other current liabilities | 19,795 | 20,358 | |||||
| Lease liabilities | 1,162 | 974 | |||||
| Total current liabilities | 26,253 | 25,876 | |||||
| Long-term lease liabilities | 9,878 | 11,322 | |||||
| Other long-term liabilities | — | 127 | |||||
| Total liabilities | 36,131 | 37,325 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Common stock, 41,242,005 shares issued and outstanding as of December 31, 2025 and 40,428,220 shares issued and outstanding as of December 31, 2024 | 41 | 40 | |||||
| Preferred stock, and outstanding | — | — | |||||
| Additional paid-in capital | 936,628 | 903,127 | |||||
| Accumulated other comprehensive loss | 53 | 166 | |||||
| Accumulated deficit | (661,039 | ) | (622,095 | ) | |||
| Total stockholders' equity | 275,683 | 281,238 | |||||
| Total liabilities and stockholders' equity | $ | 311,814 | $ | 318,563 | |||
Non-GAAP Financial Measures
To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.
We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share
Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.
Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:
| Three months ended December 31, | Year ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Common Stock | ||||||||||||||||
| Numerator: | ||||||||||||||||
| Net loss available to stockholders, basic and diluted | $ | (9,151 | ) | $ | (5,938 | ) | $ | (38,944 | ) | $ | (27,455 | ) | ||||
| Add: | ||||||||||||||||
| Stock-based compensation | 7,818 | 7,282 | 31,612 | 24,635 | ||||||||||||
| Adjusted net (loss) income available to common stockholders, basic and diluted: | $ | (1,333 | ) | $ | 1,344 | $ | (7,332 | ) | $ | (2,820 | ) | |||||
| Denominator: | ||||||||||||||||
| Weighted-average shares outstanding, basic | 41,175,725 | 40,356,756 | 40,850,739 | 38,867,726 | ||||||||||||
| Weighted-average shares outstanding, diluted | 41,175,725 | 45,622,429 | 40,850,739 | 38,867,726 | ||||||||||||
| Adjusted net earnings (loss) per share, basic | $ | (0.03 | ) | $ | 0.03 | $ | (0.18 | ) | $ | (0.07 | ) | |||||
| Adjusted net earnings (loss) per share, diluted | $ | (0.03 | ) | $ | 0.03 | $ | (0.18 | ) | $ | (0.07 | ) | |||||
FAQ
What were RxSight's full-year 2025 revenue and net loss (RXST)?
How many Light Adjustable Lenses (LAL) did RXST sell in 2025 and what was the growth?
What guidance did RxSight give for 2026 revenue, gross margin, and operating expenses (RXST)?
Why did RxSight's gross margin improve in 2025 despite lower revenue (RXST)?
How did RxSight perform in the fourth quarter of 2025 and what were key drivers (RXST)?
